Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Time to glaucoma progression detection by retinal nerve fiber layer thickness and visual field in individuals of African descent
Jo-Hsuan Wu; Sasan Moghimi; Evan Walker; Takashi Nishida; Gopikasree Gunasegaran; Natchada Tansuebchueasai; Jeffrey M Liebmann; Massimo Antonio Fazio; Christopher A Girkin; Linda M Zangwill; Robert Weinreb
Author Affiliations & Notes
  • Jo-Hsuan Wu
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Sasan Moghimi
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Evan Walker
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Takashi Nishida
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Gopikasree Gunasegaran
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Natchada Tansuebchueasai
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Jeffrey M Liebmann
    Edward S Harkness Eye Institute, New York, New York, United States
  • Massimo Antonio Fazio
    Department of Ophthalmology and Vision Sciences, Heersink School of Medicine, University of Alabama-Birmingham, Alabama, United States
  • Christopher A Girkin
    Department of Ophthalmology and Vision Sciences, Heersink School of Medicine, University of Alabama-Birmingham, Alabama, United States
  • Linda M Zangwill
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Robert Weinreb
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Jo-Hsuan Wu None; Sasan Moghimi National Eye Institute, Code F (Financial Support); Evan Walker None; Takashi Nishida Topcon, Code C (Consultant/Contractor); Gopikasree Gunasegaran None; Natchada Tansuebchueasai None; Jeffrey Liebmann Allergan, Genentech, Thea, Bausch & Lomb, Code C (Consultant/Contractor), Novartis, Research to Prevent Blindness , Code F (Financial Support); Massimo Fazio National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Topcon and Wolfram Research, Code F (Financial Support); Christopher Girkin National Eye Institute,Heidelberg Engineering and Topcon, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Code F (Financial Support); Linda Zangwill Abbvie Inc. Topcon, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc., Code F (Financial Support), Carl Zeiss Meditec, AiSight Health, Code P (Patent), AiSight Health, Code S (non-remunerative); Robert Weinreb bbvie, Aerie Pharmaceuticals, Allergan, Equinox, Iantrek, Implandata, Nicox, Topcon Medical, Code C (Consultant/Contractor), Bausch & Lomb, Topcon Medical, Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Centervue, Code F (Financial Support), Toromedes, Carl Zeiss Meditec, Code P (Patent), Toromedes, Code S (non-remunerative)
  • Footnotes
    Support  National Institutes of Health/National Eye Institute Grants R01EY029058, R01EY011008, R01EY019869, R01EY027510, R01EY026574, R01EY018926, R01EY034148, Core grant P30EY022589; University of California Tobacco Related Disease Research Program (T31IP1511), and an unrestricted grant from Research to Prevent Blindness (New York, NY)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2509. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Time to glaucoma progression detection by retinal nerve fiber layer thickness and visual field in individuals of African descent
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Jo-Hsuan Wu, Sasan Moghimi, Evan Walker, Takashi Nishida, Gopikasree Gunasegaran, Natchada Tansuebchueasai, Jeffrey M Liebmann, Massimo Antonio Fazio, Christopher A Girkin, Linda M Zangwill, Robert Weinreb; Time to glaucoma progression detection by retinal nerve fiber layer thickness and visual field in individuals of African descent. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2509.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To examine the time to glaucoma progression detection by retinal nerve fiber layer thickness (RNFLT) and visual field (VF) among African descent (AD) individuals.

Methods : We included primary open angle glaucoma eyes from DIGS/ADAGES subjects self-identified as AD with ≥2-year/5-visits of optic nerve head RNFLT and VF examinations. Rates of VF mean deviation (MD) and RNFLT change were analyzed using linear mixed-effects models, and the variability estimates were used to simulate longitudinal data. The simulated time to detect trend-based glaucoma progression was assessed with assumed rates of VF and RNFLT change derived from the cohort (25th, 50th, 75th percentile [i.e. p25, median, p75] slopes and mean slopes). Sensitivity analyses were performed by stratifying the eyes into mild and moderate-advanced glaucoma.

Results : We included 184 eyes (mild glaucoma, n=138; moderate-advanced glaucoma, n=46) from 128 AD subjects (mean baseline age: 63.4 years; 24-2 VF MD: -4.2 dB, RNFLT: 80.2 µm). The overall RNFLT and VF MD variability was 2.4 µm and 1.1 dB, respectively. The p25, median, mean and p75 rates of change were -0.43, -1.01, -1.15 and -1.64 µm/year for RNFLT, and 0.00, -0.21, -0.30 and -0.51 dB/year for VF MD, respectively. Overall, compared to VF MD, RNFLT showed a faster mean time to progression detection (time difference: 0.4-1.7 years), with the longest lead time difference observed for the median rates (RNFLT: 5.2 years vs. VF MD: 6.9 years) (see Table 1). Similar to overall results, we found an overall shorter time (≥ 1 year faster) to detecting RNFLT progression, compared to that of VF MD progression, in mild glaucoma eyes. For moderate-advanced glaucoma eyes, RNFLT again demonstrated faster progression detection than VF MD by approximately 0.5 year.

Conclusions : Computer simulation showed potentially faster time to detect RNFLT progression than VF MD progression in AD eyes. Our findings support the importance of using RNFLT to detect progressive glaucoma in AD individuals.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Table 1. Required time to detect progression in African descent glaucoma eyes
View OriginalDownload Slide

Table 1. Required time to detect progression in African descent glaucoma eyes

Table 1. Required time to detect progression in African descent glaucoma eyes

Table 1. Required time to detect progression in African descent glaucoma eyes
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept